Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | RAF1 | P04049 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11247732 | 0.86 | CASP6 (0.57) | VCAM1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL1186419 | 0.84 | VCAM1 (0.49) | VCAM1ALDH1A1MAPTLMNAHPGD | |
| SCHEMBL1026971 | 0.84 | TSHR (0.62) | VCAM1ALDH1A1MAPTLMNAHPGD | |
| SCHEMBL51755 | 0.83 | LMNA (0.72) | VCAM1ALDH1A1MAPTLMNAHPGD | |
| SCHEMBL10540425 | 0.83 | ALDH1A1 (0.45) | VCAM1ALDH1A1MAPTLMNAHPGD | |
| SCHEMBL1931416 | 0.82 | VCAM1 (0.55) | VCAM1ALDH1A1MAPTLMNAHPGD | |
| SCHEMBL15726876 | 0.82 | VCAM1 (0.55) | VCAM1ALDH1A1MAPTLMNAHPGD | |
| SCHEMBL22230563 | 0.82 | VCAM1 (0.48) | VCAM1ALDH1A1MAPTLMNAHPGD | |
| SCHEMBL1570007 | 0.82 | ITGB1 (0.53) | VCAM1ALDH1A1MAPTLMNAHPGD | |
| SCHEMBL2983672 | 0.82 | PARP1 (0.59) | VCAM1ALDH1A1MAPTLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2026-05-26 | — | — | US | disclosed |
| CN-113286777-B | Compounds, compositions and methods for modulating iron death and treating excitotoxic disorders | 纽约市哥伦比亚大学理事会 | 2024-10-29 | — | — | CN | disclosed |
| US-20240156790-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-05-16 | — | — | US | disclosed |
| EP-4347605-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | The Trustees of Columbia University in the City of New York (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117677623-A | Compounds, compositions and methods for modulating iron death and treating excitotoxic disorders | 纽约市哥伦比亚大学理事会 | 2024-03-08 | — | — | CN | disclosed |
| US-20230113588-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-13 | — | — | US | disclosed |
| WO-2022251306-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-01 | — | — | WO | disclosed |
| US-11447453-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-09-20 | — | — | US | disclosed |
| EP-3154954-B1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3887351-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | The Trustees of Columbia University in the City of New York (US) | 2021-10-06 | — | — | EP | disclosed |
| US-6156758-A | Antibacterial quinazoline compounds | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-05 | — | — | US | disclosed |
| WO-2000063197-A1 | HYDROXAMIC ACID DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-10-26 | — | — | WO | disclosed |
| US-6071908-A | A RADIATION-ACTIVATED CYTOTOXIN PRODRUG HAVING LOW TOXICITY, WHICH CAN BE REDUCED BY REDUCING AGENTS GENERATED BY THE RADIOLYSIS OF WATER WHICH RELEASES AN CYTOXIC EFFECTOR; ANTITUMOR,-CARCINOGENIC AGENTS; | AUCKLAND UNISERVICES LIMITED (NZ) | 2000-06-06 | — | — | US | disclosed |
| US-5985909-A | Cyclopropylindoles and their seco precursors, and their use as prodrugs | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-11-16 | — | — | US | disclosed |
| EP-0850220-A1 | CYCLOPROPYLINDOLES AND THEIR SECO PRECURSORS, AND THEIR USE AS PRODRUGS | AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND INC. (NZ) | 1998-07-01 | — | — | EP | disclosed |
| EP-0850224-A1 | RADIATION-ACTIVATED CYTOTOXIN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997007101-A1 | RADIATION-ACTIVATED CYTOTOXIN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 1997-02-27 | — | — | WO | disclosed |
| WO-1997007097-A1 | CYCLOPROPYLINDOLES AND THEIR SECO PRECURSORS, AND THEIR USE AS PRODRUGS | AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND INC. (NZ) | 1997-02-27 | — | — | WO | disclosed |
| US-5461046-A | Analgesics | G. D. SEARLE & CO. (US) | 1995-10-24 | — | — | US | disclosed |
| US-5304644-A | 1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain | G. D. SEARLE & CO. (US) | 1994-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156790-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | AIFM2, GPX1, SLC7A11 | VCAM1 2881/4885ALDH1A1 2287/4885MAPT 91/4885 |
| US-11447453-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | VCAM1 4070/4885ALDH1A1 4541/4885MAPT 829/4885 |
| US-20230113588-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | VCAM1 4070/4885ALDH1A1 4541/4885MAPT 829/4885 |
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | VCAM1 3345/4885ALDH1A1 3385/4885MAPT 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.